Alison McVie-Wylie, PhD
Vice President, Preclinical Development
Alison McVie-Wylie joined Exonics Therapeutics as Vice President of Preclinical Development in 2018. Prior to Exonics, Alison served as the Head of Gene Therapy and Biologics Pharmacology in the Rare Disease Research group at Sanofi. Alison was previously at Genzyme where she gained extensive experience advancing innovative novel biotherapeutics from preclinical research into clinical development in multiple disease areas, including neuromuscular, metabolic, ocular, immunology and multiple sclerosis. She has supported numerous global regulatory submissions and was the lead Scientist responsible for the nonclinical development of Myozyme® and Lumizyme® from early concept to IND and worldwide licensure. Prior to Sanofi/Genzyme, Alison worked in the laboratory of Dr. Y.T. Chen at Duke University on the early development of enzyme replacement therapy as a treatment for Pompe Disease. At Duke University, Alison became board certified in Clinical Molecular Genetics. Alison obtained her Ph.D. in Molecular Genetics from the University of Glasgow, Scotland, and a B.Sc. (1st class) in Biochemistry and Immunology from the University of Strathclyde, Glasgow, Scotland.